About the Company
acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACER News
Bayer to seek approval for menopausal relief drug after third trial win
Bayer said on Tuesday that it would request regulatory approval for its menopause drug after the daily pill was shown to ease ...
Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know
Acer Therapeutics Inc. (ACER) closed at $1.67 in the latest trading session, marking a -1.76% move from the prior day. This change lagged the S&P 500's 1.45% loss on the day. At the same time ...
Acer Therapeutics Inc Stock (OTC:ACER), Insider Trading Activity
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...
Acer Therapeutics (ACER) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.19%
The worst performers were Lifecore Biomedical Inc (NASDAQ:LFCR) which was down 67.32% to 1.67 in late trade, Acer Therapeutics Inc (NASDAQ:ACER) which lost 56.77% to settle at 0.67 and Loyalty ...
Moving iMage Technologies Stock (AMEX:MITQ), Quotes and News Summary
Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
CADL Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical ...
Kintara Therapeutics Inc KTRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Loading the latest forecasts...